<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01271751</url>
  </required_header>
  <id_info>
    <org_study_id>GFT505-208-3</org_study_id>
    <secondary_id>2008-005779-86</secondary_id>
    <nct_id>NCT01271751</nct_id>
  </id_info>
  <brief_title>Pilot Study With GFT505 (80mg) in Atherogenic Dyslipidaemic Patients With Abdominal Obesity</brief_title>
  <official_title>A Pilot Study to Evaluate the Efficacy and Safety of GFT505 (80mg) Orally Administered Once Daily for 28 Days in Atherogenic Dyslipidaemic Patients With Abdominal Obesity. A Double Blind, Placebo-controlled and Randomized Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genfit</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genfit</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy of GFT505 80mg in reducing serum
      Triglycerides (TG) and increasing High Density Lipoprotein Cholesterol (HDL-C) levels
      compared with placebo in atherogenic dyslipidaemic patients with abdominal obesity, and to
      assess the tolerability and safety of once-a-day administrations of oral doses of GFT505
      during 28 days.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study period per patient is 7 to 14 weeks: a screening period (1 to 8 weeks) will precede
      a 4-week double-blind treatment period and a 2-week follow-up period.

      During the screening period, patients will be asked to start or continue adequate diet and
      exercise and to stop their lipid-lowering medication (for not treatment-naïve patients). For
      patient taking any lipid-regulating medication, a minimum of 8-week wash-out from
      lipid-regulating therapies (fibrates, statins, …) is required.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">November 2009</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Decrease in serum Triglycerides (TG) level</measure>
    <time_frame>28 days</time_frame>
    <description>To evaluate the efficacy of GFT505 80mg in reducing serum TG compared with placebo. Evaluation will be made during the selection period, then the first day prior any drug intake, 2 and 4 weeks after the first treatment intake and 2 weeks after the last treatment intake (follow-up visit)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Increase in serum High Density Lipoprotein Cholesterol (HDL-C) level</measure>
    <time_frame>28 days</time_frame>
    <description>To evaluate the efficacy of GFT505 80mg in increasing HDL-C levels compared with placebo. Evaluation will be made during the selection period, then the first day prior any drug intake, 2 and 4 weeks after the first treatment intake and 2 weeks after the last treatment intake (follow-up visit)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Decrease in Low Density Lipoprotein Cholesterol (LDL-C) levels</measure>
    <time_frame>28 days</time_frame>
    <description>To evaluate the efficacy of GFT505 80mg in reducing LDL-C levels compared with placebo. Evaluation will be made during the selection period, then the first day prior any drug intake, 2 and 4 weeks after the first treatment intake and 2 weeks after the last treatment intake (follow-up visit)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Decrease in non-HDL-C (High Density Lipoprotein Cholesterol) levels</measure>
    <time_frame>28 days</time_frame>
    <description>To evaluate the efficacy of GFT505 80mg in reducing non-HDL-C levels compared with placebo. Evaluation will be made during the selection period, then the first day prior any drug intake, 2 and 4 weeks after the first treatment intake and 2 weeks after the last treatment intake (follow-up visit)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">96</enrollment>
  <condition>Atherogenic Dyslipidaemia</condition>
  <condition>Abdominal Obesity</condition>
  <arm_group>
    <arm_group_label>GFT505 80mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Matching placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GFT505 80mg</intervention_name>
    <description>hard gelatin capsules dosed at 20mg, oral administration, 4 capsules per day before breakfast</description>
    <arm_group_label>GFT505 80mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>hard gelatin capsules, oral administration, 4 capsules per day before breakfast</description>
    <arm_group_label>Matching placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or post-menopausal female.

          -  Waist circumference ≥102cm for male, ≥ 88cm for female.

          -  Atherogenic dislipidaemia inadequately controlled despite Therapeutic Lifestyle Change
             (TLC) recommendations (diet and exercise).

          -  150≤ fasting TG ≤ 600 mg/dL (1.69 ≤ fasting TG ≤ 6.78 mmol/L) at V2.

          -  Fasting HDL-C ≤ 40 mg/dL (≤ 1.03 mmol/L) for male, HDL-C ≤ 45 mg/dL (≤ 1.16 mmol/L)
             for female at V2.

        Exclusion Criteria:

          -  Body Mass Index (BMI) ≥ 40 kg/m².

          -  Blood Pressure &gt; 160 / 95 mmHg.

          -  Type I or type II Diabetes Mellitus.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rémy Hanf, Development Director</last_name>
    <role>Study Director</role>
    <affiliation>GENFIT, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eric BRUCKERT, Pr.</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital of Paris 6, France</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site n°36</name>
      <address>
        <city>Aigrefeuille Sur Maine</city>
        <zip>44140</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site n°78</name>
      <address>
        <city>Angers</city>
        <zip>49000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site n°79</name>
      <address>
        <city>Angers</city>
        <zip>49000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site n°80</name>
      <address>
        <city>Angers</city>
        <zip>49000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site n°82</name>
      <address>
        <city>Angers</city>
        <zip>49000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site n°21</name>
      <address>
        <city>Baune</city>
        <zip>49140</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site n°16</name>
      <address>
        <city>Beaucouze</city>
        <zip>49070</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site n°18</name>
      <address>
        <city>Briollay</city>
        <zip>49125</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site n°14</name>
      <address>
        <city>Cholet</city>
        <zip>49300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site n°26</name>
      <address>
        <city>Cholet</city>
        <zip>49300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site n°42</name>
      <address>
        <city>Haute Goulaine</city>
        <zip>44115</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site n°45</name>
      <address>
        <city>Heric</city>
        <zip>44810</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site n°32</name>
      <address>
        <city>La Chapelle Sur Erdre</city>
        <zip>44240</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site n°11</name>
      <address>
        <city>La Jubaudière</city>
        <zip>49510</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site n°30</name>
      <address>
        <city>La Montagne</city>
        <zip>44620</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site n°91</name>
      <address>
        <city>Laval</city>
        <zip>53000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site n°23</name>
      <address>
        <city>Le Mesnil en Vallée</city>
        <zip>49410</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site n°35</name>
      <address>
        <city>le Temple de Bretagne</city>
        <zip>44360</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site n°12</name>
      <address>
        <city>Les Ponts de Ce</city>
        <zip>49130</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site n°17</name>
      <address>
        <city>Montreuil Juigne</city>
        <zip>49460</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site n°74</name>
      <address>
        <city>Montrevault</city>
        <zip>49110</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site n°10</name>
      <address>
        <city>Murs-Erigné</city>
        <zip>49610</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site n°19</name>
      <address>
        <city>Murs-Erigné</city>
        <zip>49610</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site n°40</name>
      <address>
        <city>Nantes</city>
        <zip>44000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site n°37</name>
      <address>
        <city>Nantes</city>
        <zip>44100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site n°31</name>
      <address>
        <city>Nantes</city>
        <zip>44300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site n°34</name>
      <address>
        <city>Nantes</city>
        <zip>44300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site n°41</name>
      <address>
        <city>Nort sur Erdre</city>
        <zip>44390</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site n°33</name>
      <address>
        <city>Orvault</city>
        <zip>44700</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site n°1</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site n°39</name>
      <address>
        <city>Sautron</city>
        <zip>44880</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site n°13</name>
      <address>
        <city>Segre</city>
        <zip>49500</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site n°38</name>
      <address>
        <city>St Etienne de Montluc</city>
        <zip>44360</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site n°75</name>
      <address>
        <city>Tierce</city>
        <zip>49125</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site n°77</name>
      <address>
        <city>Tierce</city>
        <zip>49125</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site n°20</name>
      <address>
        <city>Vihiers</city>
        <zip>49310</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site n°64</name>
      <address>
        <city>Brasov</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site n°61</name>
      <address>
        <city>Bucharest</city>
        <zip>010243</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site n°60</name>
      <address>
        <city>Bucharest</city>
        <zip>Sector 2</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site n°63</name>
      <address>
        <city>Bucharest</city>
        <zip>Sector 2</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site n°62</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site n°65</name>
      <address>
        <city>Craiova</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site n°52</name>
      <address>
        <city>Bab Sâadoun Tunis</city>
        <zip>1029</zip>
        <country>Tunisia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site n°53</name>
      <address>
        <city>Bab Sâadoun Tunis</city>
        <zip>1029</zip>
        <country>Tunisia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site n°50</name>
      <address>
        <city>Tunis</city>
        <zip>1007</zip>
        <country>Tunisia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site n°51</name>
      <address>
        <city>Tunis</city>
        <zip>1007</zip>
        <country>Tunisia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site n°55</name>
      <address>
        <city>Tunis</city>
        <zip>1089</zip>
        <country>Tunisia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Romania</country>
    <country>Tunisia</country>
  </location_countries>
  <verification_date>January 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 6, 2011</study_first_submitted>
  <study_first_submitted_qc>January 6, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 7, 2011</study_first_posted>
  <last_update_submitted>January 6, 2011</last_update_submitted>
  <last_update_submitted_qc>January 6, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 7, 2011</last_update_posted>
  <responsible_party>
    <name_title>Product Development Department</name_title>
    <organization>Genfit</organization>
  </responsible_party>
  <keyword>Atherogenic-dyslipidaemia</keyword>
  <keyword>PPARs</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Dyslipidemias</mesh_term>
    <mesh_term>Obesity, Abdominal</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

